NovAccess Global Announces New License to Advance its Immunotherapy Platform
Accesswire
*CLEVELAND, OH / ACCESSWIRE / April 30, 2024 /* NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing a novel..
*CLEVELAND, OH / ACCESSWIRE / April 30, 2024 /* NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing a novel..
CLOSED 6 BILLION DOLLAR SERIES B DEAL
SAN FRANCISCO, April 04, 2024 (GLOBE NEWSWIRE) -- Silicon Valley-based..
Dublin, March 05, 2024 (GLOBE NEWSWIRE) -- The "Collaboration Deals in Biotechnology 2019-2024" report has been added to *..